Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Adaptive Biotechnologies Q4 2023 Adj EPS $(0.30) Beats $(0.33) Estimate, Sales $45.78M Miss $48.46M Estimate

Author: Benzinga Newsdesk | February 14, 2024 05:25pm
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. The company reported quarterly sales of $45.78 million which missed the analyst consensus estimate of $48.46 million by 5.52 percent. This is a 17.05 percent decrease over sales of $55.20 million the same period last year.

Posted In: ADPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist